S. Schierle

发表

A triple farnesoid X receptor and peroxisome proliferator-activated receptor α/δ activator reverses hepatic fibrosis in diet-induced NASH in mice

S. Müller, D. Merk, M. Schröder, 2020, Communications Chemistry.

A selective modulator of peroxisome proliferator-activated receptor γ with unprecedented binding mode.

S. Knapp, O. Werz, M. Windbergs, 2020, Journal of medicinal chemistry.

Computer‐Assisted Selective Optimization of Side‐Activities—from Cinalukast to a PPARα Modulator

D. Merk, A. Kaiser, Julius Pollinger, 2019, ChemMedChem.

A Novel Biphenyl-based Chemotype of Retinoid X Receptor Ligands Enables Subtype and Heterodimer Preferences.

S. Knapp, A. Chaikuad, D. Merk, 2019, ACS medicinal chemistry letters.

Development and in vitro Profiling of Dual FXR/LTA4H Modulators

D. Steinhilber, E. Proschak, J. Kramer, 2021, ChemMedChem.

Design and Structural Optimization of Dual FXR/PPARδ Activators.

D. Merk, Pascal Heitel, A. Kaiser, 2020, Journal of medicinal chemistry.

Structure-Based Design of Dual Partial Peroxisome Proliferator-Activated Receptor γ Agonists/Soluble Epoxide Hydrolase Inhibitors.

S. Knapp, D. Steinhilber, E. Proschak, 2021, Journal of medicinal chemistry.

Structural optimization and in vitro profiling of N-phenylbenzamide-based farnesoid X receptor antagonists.

D. Merk, A. Kaiser, Jurema Schmidt, 2018, Bioorganic & medicinal chemistry.

Selective Optimization of Pranlukast to Farnesoid X Receptor Modulators

D. Merk, A. Kaiser, Jurema Schmidt, 2018, ChemMedChem.

A New FXR Ligand Chemotype with Agonist/Antagonist Switch.

D. Merk, A. Kaiser, Jurema Schmidt, 2021, ACS medicinal chemistry letters.

Activity Screening of Fatty Acid Mimetic Drugs Identified Nuclear Receptor Agonists

E. Proschak, D. Merk, J. Marschner, 2022, International journal of molecular sciences.

Oxaprozin Analogues as Selective RXR Agonists with Superior Properties and Pharmacokinetics.

S. Knapp, E. Proschak, A. Chaikuad, 2021, Journal of medicinal chemistry.

Tuning Nuclear Receptor Selectivity of Wy14,643 towards Selective Retinoid X Receptor Modulation.

E. Proschak, D. Merk, J. Heering, 2019, Journal of medicinal chemistry.

Therapeutic modulation of retinoid X receptors – SAR and therapeutic potential of RXR ligands and recent patents

D. Merk, S. Schierle, 2019, Expert opinion on therapeutic patents.

Boosting Anti-Inflammatory Potency of Zafirlukast by Designed Polypharmacology.

D. Steinhilber, M. Wurglics, E. Proschak, 2018, Journal of medicinal chemistry.

Development and Profiling of Inverse Agonist Tools for the Neuroprotective Transcription Factor Nurr1.

D. Merk, J. Heering, S. Schierle, 2021, Journal of medicinal chemistry.

Dual Farnesoid X Receptor/Soluble Epoxide Hydrolase Modulators Derived from Zafirlukast

E. Proschak, D. Merk, Pascal Heitel, 2019, ChemMedChem.

Development of Nuclear Receptor Modulators.

D. Merk, S. Schierle, 2018, Methods in molecular biology.